StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) Announces VIZIMPRO Receives MAA in EU for First-Line Treatment of Adult Patients with EGFR-Mutated NSCLC
April 3, 2019 9:43 AM
(Updated - April 3, 2019 9:44 AM EDT)Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
April 3, 2019 9:42 AM
